ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 212,22
0,55%
Dow Jones
40 003,59
0,00%
DAX
18 797,52
0,48%
Brent Oil
83,425
-0,20%
Bitcoin
67 071,06
1,38%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) Actualités

ASND

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ASND
DateHeureSourceTitreSymboleSociété
16/05/202422h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
14/05/202420h31GlobeNewswire Inc.Ascendis Pharma Announces Extension of U.S. Food and Drug Administration Review Period for TransCon™ PTH for Adults with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
13/05/202414h30GlobeNewswire Inc.Significant and Sustained Improvements in Renal Function Reported for Adults with Chronic Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide): 2-year Results from Phase 3 PaTHway TrialNASDAQ:ASNDAscendis Pharma AS
09/05/202414h30GlobeNewswire Inc.Latest Clinical and Quality-of-Life Data for TransCon™ PTH (Palopegteriparatide)-Treated Adults with Chronic Hypoparathyroidism to Be Presented at ECE 2024NASDAQ:ASNDAscendis Pharma AS
02/05/202422h01GlobeNewswire Inc.Ascendis Pharma Reports First Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
25/04/202422h46GlobeNewswire Inc.Ascendis Pharma to Report First Quarter 2024 Financial Results and Provide Business Update on May 2, 2024NASDAQ:ASNDAscendis Pharma AS
24/04/202414h30GlobeNewswire Inc.United Kingdom’s MHRA Approves YORVIPATH® (palopegteriparatide) in Great Britain for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
07/03/202417h31Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
04/03/202414h30GlobeNewswire Inc.Ascendis Pharma to Participate in the Leerink Partners Global Biopharma Conference 2024NASDAQ:ASNDAscendis Pharma AS
14/02/202415h17Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ASNDAscendis Pharma AS
07/02/202422h15Edgar (US Regulatory)Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]NASDAQ:ASNDAscendis Pharma AS
07/02/202422h01GlobeNewswire Inc.Ascendis Pharma Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:ASNDAscendis Pharma AS
07/02/202414h30GlobeNewswire Inc.Ascendis Pharma to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:ASNDAscendis Pharma AS
31/01/202422h15GlobeNewswire Inc.Ascendis Pharma to Report Full Year 2023 Financial Results and Provide Business Update on February 7, 2024NASDAQ:ASNDAscendis Pharma AS
31/01/202422h01GlobeNewswire Inc.Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
29/01/202414h30GlobeNewswire Inc.New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External InvestorsNASDAQ:ASNDAscendis Pharma AS
08/01/202414h20GlobeNewswire Inc.Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries NASDAQ:ASNDAscendis Pharma AS
07/01/202423h45GlobeNewswire Inc.Ascendis Pharma Introduces Vision 2030NASDAQ:ASNDAscendis Pharma AS
07/01/202420h00PR Newswire (US)Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countriesNASDAQ:ASNDAscendis Pharma AS
28/12/202322h15GlobeNewswire Inc.Ascendis Pharma to Participate in the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ASNDAscendis Pharma AS
20/12/202314h30GlobeNewswire Inc.Significant Health and Quality of Life Improvements Achieved in Children with Achondroplasia Treated for One Year with TransCon™ CNP (Navepegritide) at 100 µg/kg/weekNASDAQ:ASNDAscendis Pharma AS
19/12/202314h30GlobeNewswire Inc.TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
11/12/202314h30GlobeNewswire Inc.FDA Accepts for Review Resubmitted NDA for TransCon PTH (Palopegteriparatide) in Adult Patients with HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
29/11/202310h30GlobeNewswire Inc.Ascendis Pharma Announces Strategic Partnership with Teijin Limited in JapanNASDAQ:ASNDAscendis Pharma AS
20/11/202314h00GlobeNewswire Inc.Ascendis Pharma Announces European Commission Approval of YORVIPATH® (palopegteriparatide) for the Treatment of Adults with Chronic HypoparathyroidismNASDAQ:ASNDAscendis Pharma AS
15/11/202314h00GlobeNewswire Inc.Ascendis Pharma Resubmits NDA for TransCon™ PTH to the U.S. FDANASDAQ:ASNDAscendis Pharma AS
07/11/202322h01GlobeNewswire Inc.Ascendis Pharma Reports Third Quarter 2023 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
31/10/202313h30GlobeNewswire Inc.Ascendis Pharma Announces Timing of Third Quarter 2023 Financial Results and TransCon PTH NDA ResubmissionNASDAQ:ASNDAscendis Pharma AS
26/10/202314h30GlobeNewswire Inc.Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023NASDAQ:ASNDAscendis Pharma AS
16/10/202322h01GlobeNewswire Inc.Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023NASDAQ:ASNDAscendis Pharma AS
 Showing the most relevant articles for your search:NASDAQ:ASND

Dernières Valeurs Consultées

NASDAQI
FN10PI
First North Technology PI
TG
0FY
Equillium
USOTC
JGLMY
Jiang Ling Motors (PK)
BIT
P1VM50
NLBNPIT1VM50 20991231 27...
NASDAQI
ONEQT
Fidelity Nasdaq Composite
TSX
IIMF
Invesco International De...
USOTC
GIGPF
Giga Prize (PK)
EU
EUSG
Euronext USA GR
AMEX
DDM
ProShares Ultra Dow30
DOWI
DRMA
USOTC
FPVTF
Golden Pursuit Resources (PK)
TG
0UI
American Coastal Insurance
TG
DJDA
Dieteren
LSE
JEGP
Jpm Gl Eq Pi D
AMEX
ROM
ProShares Ultra Technology
NASDAQ
FEIAAX
Dorsey Wright Relative S...
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés